黑料网

Journal of Pharmacokinetics & Experimental Therapeutics
黑料网

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 黑料网 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

黑料网 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Mini Review   
  • J Pharmacokinet Exp Ther,

Redefining Drug Development: Artificial Intelligence's Part Redefining Drug Development: Artificial Intelligence

PartGerick Wilson*
Department of Pharmacology, University of Otago, New Zealand
*Corresponding Author : PartGerick Wilson, Department of Pharmacology, University of Otago, New Zealand, Email: gerickwilson324@student.otago.ac.nz

Received Date: Apr 01, 2024 / Accepted Date: Apr 30, 2024 / Published Date: Apr 30, 2024

Abstract

Artificial intelligence (AI) has emerged as a transformative force in the field of drug discovery, revolutionizing traditional approaches and expediting the development of novel therapeutics. This abstract explores the pivotal role of AI in various stages of drug discovery, including target identification, compound design, virtual screening, predictive toxicology, clinical trial optimization, and drug repurposing. By harnessing the power of machine learning algorithms and big data analytics, AI enables researchers to navigate complex biological systems, identify promising drug targets, design optimized compounds, and accelerate clinical trials. Moreover, AI facilitates the repurposing of existing drugs for new indications, offering a cost-effective and time-efficient strategy for addressing unmet medical needs. The integration of AI into drug discovery processes holds immense promise for advancing healthcare, improving patient outcomes, and ushering in a new era of precision medicine.

Citation: PartGerick W (2024) Redefining Drug Development: Artificial Intelligence'sPartRedefining Drug Development: Artificial Intelligence . J Pharmacokinet ExpTher 8: 231.

Copyright: © 2024 PartGerick W. This is an open-access article distributed underthe terms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.

International Conferences 2024-25
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top